Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Milrinone infusion

Phase 3

NNICHD Neonatal Research Network

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Post-Ligation Cardiac SyndromeRecruiting

Post-Ligation Cardiac SyndromePhase 3

Recruiting

Timeline

Expected Milestones

Q2 2029

Phase 3Recruiting

Post-Ligation Cardiac Syndrome

NCT06679855

Clinical

Trials by Indication[1]

Post-ligation Cardiac Syndrome1 trial

Milrinone for Prevention of Post-ligation Cardiac Syndrome Trial

Recruiting·NNICHD Neonatal Research Network·Phase 3·NCT06679855·316 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Milrinone infusion. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Milrinone infusion. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — NICHD Neonatal Research Network company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: NNICHD Neonatal Research Network

Related News